Ischemaview, Inc.

Ischemaview, Inc., a Golden, Colorado-based medical imaging analytics software company, operates as a prime contractor exclusively serving the Department of Veterans Affairs, delivering RapidAI — a clinical decision support platform designed for stroke and neurological diagnostic support — across VA health systems. Ischemaview competes full-and-open (no set-aside designation on 13 of 19 recent awards) and holds a small business designation; the company executes 100 percent of its work as prime, with no identified subcontract footprint.

Ischemaview's customer base is entirely concentrated within the VA system, with five distinct customer entities accounting for all 19 recent awards totaling $5.7 million in combined potential value. The Department of Veterans Affairs Technology Acquisition Center Austin anchors the dollar ranking with a single $3.8 million definitive contract awarded September 22, 2026, for RapidAI Enterprise Implementation supporting the National Telestroke Program across 80+ VA telestroke sites. This firm fixed-price contract runs through September 21, 2029, with baseline capacity of 6,000 patients annually, optional expansion to 7,500 patients per period, and deliverables spanning software licenses, three 30-day phased implementation, 24/7/365 technical support with severity-based response targets from 1 hour to 3 business days, managed services sustainment, algorithm enhancements, and training. The contract requires compliance with VA Critical Security Controls, FICAM authentication standards, IPv6 compliance, TIC 3.0 standards, and OMB M-26-04 AI governance requirements, with place of performance in Palo Alto, California. By award count, Veterans Integrated Service Network 10 dominates with 13 awards totaling $964 thousand, followed by VISN 21 (3 awards, $473 thousand), VISN 17 ($223 thousand), and VISN 7 ($221 thousand).

Ischemaview holds three active IDCs under VISN entities. The largest is a $210 thousand single-award IDIQ (36C25023D0040) designated Total Small Business, awarded March 7, 2023, carrying an ultimate completion date of February 29, 2028, from which four delivery orders totaling $337 thousand have been issued for RapidAI software and neuroimaging modules. A $175 thousand single-award IDIQ (36C25025D0009) awarded November 1, 2024, to VISN 10 carries a completion date of October 31, 2029 and funds RapidAI software and Diversity, Equity, and Inclusion capability implementation; two delivery orders valued at $70 thousand total have been placed. A third IDIQ (36C25019D0084) supports four task orders totaling $78 thousand. Representative delivery orders include a $42 thousand order from VISN 10 awarded March 1, 2026, for RapidAI software implementation in Golden, Colorado (completion February 28, 2027), a $222.6 thousand purchase order from VISN 17 awarded April 10, 2023, under Total Small Business set-aside for RapidAI software with completion April 9, 2028, and a $221 thousand order from VISN 7 awarded March 13, 2023, for RapidAI software with completion March 5, 2028.

Activity reflects moderate recent growth (five awards in 2023, declining to two in 2026), with six awards totaling $773 thousand in combined potential value facing ultimate completion within the next twenty-four months, exposing the vendor to recompete risk across its core VISN 10 and VISN 21 IDIQ base. Ischemaview's capability set is narrowly focused on FDA-cleared AI-enabled medical imaging analytics, neuroimaging modules for stroke diagnostic support, and clinical decision support software — no diversification into other VA service lines or federal customers is evident in the award record. Place of performance clusters around Golden, Colorado (company headquarters) and subordinate VA medical center sites in Indianapolis, Detroit, and Palo Alto.